Trials / Completed
CompletedNCT00620230
Safety and Tolerability of Single and Multiple Doses of VAK694 in Healthy and Atopic Subjects
A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetic Profile and Pharmacodynamic Effect of Single and Multiple Doses of VAK694 in Healthy and Atopic Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 46 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
This study will evaluate the safety and tolerability of single and multiple doses of VAK694 in healthy volunteers and otherwise healthy volunteers with a history of allergies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NVP-VAK694 | |
| DRUG | NVP-VAK694 |
Timeline
- Start date
- 2007-10-01
- Primary completion
- 2008-04-01
- Completion
- 2008-04-01
- First posted
- 2008-02-21
- Last updated
- 2010-09-27
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00620230. Inclusion in this directory is not an endorsement.